- Home
- ACIU vs FINW Comparison
ACIU vs FINW Comparison
Compare ACIU & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- FINW
- Stock Information
- Founded
- ACIU 2003
- FINW 1999
- Country
- ACIU Switzerland
- FINW United States
- Employees
- ACIU N/A
- FINW N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- FINW Commercial Banks
- Sector
- ACIU Health Care
- FINW Finance
- Exchange
- ACIU Nasdaq
- FINW Nasdaq
- Market Cap
- ACIU 213.3M
- FINW 207.1M
- IPO Year
- ACIU 2016
- FINW 2021
- Fundamental
- Price
- ACIU $2.14
- FINW $18.09
- Analyst Decision
- ACIU Strong Buy
- FINW Buy
- Analyst Count
- ACIU 1
- FINW 4
- Target Price
- ACIU $12.00
- FINW $20.75
- AVG Volume (30 Days)
- ACIU 162.6K
- FINW 19.4K
- Earning Date
- ACIU 08-05-2025
- FINW 07-24-2025
- Dividend Yield
- ACIU N/A
- FINW N/A
- EPS Growth
- ACIU N/A
- FINW N/A
- EPS
- ACIU N/A
- FINW 0.96
- Revenue
- ACIU $36,362,036.00
- FINW $75,327,000.00
- Revenue This Year
- ACIU N/A
- FINW $50.70
- Revenue Next Year
- ACIU $533.21
- FINW $22.82
- P/E Ratio
- ACIU N/A
- FINW $19.17
- Revenue Growth
- ACIU 86.71
- FINW 11.23
- 52 Week Low
- ACIU $1.43
- FINW $11.65
- 52 Week High
- ACIU $3.98
- FINW $20.94
- Technical
- Relative Strength Index (RSI)
- ACIU 49.10
- FINW 69.26
- Support Level
- ACIU $2.05
- FINW $16.96
- Resistance Level
- ACIU $2.50
- FINW $18.50
- Average True Range (ATR)
- ACIU 0.20
- FINW 0.58
- MACD
- ACIU -0.03
- FINW 0.09
- Stochastic Oscillator
- ACIU 20.00
- FINW 86.01
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.